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Mutations in the COL3A1 gene that encodes the chains of type III procollagen result in the vascular form of Ehlers-
Danlos syndrome (EDS), EDS type IV, if they alter the sequence in the triple-helical domain. Although other fibrillar
collagen–gene mutations that lead to allele instability or failure to incorporate proa-chains into trimers—and that
thus reduce the amount of mature molecules produced—result in clinically apparent phenotypes, no such mutations
have been identified in COL3A1. Furthermore, mice heterozygous for Col3a1 “null” alleles have no identified
phenotype. We have now found three frameshift mutations (1832delAA, 413delC, and 555delT) that lead to
premature termination codons (PTCs) in exons 27, 6, and 9, respectively, and to allele-product instability. The
mRNA from each mutant allele was transcribed efficiently but rapidly degraded, presumably by the mechanisms
of nonsense-mediated decay. In a fourth patient, we identified a point mutation, in the final exon, that resulted in
a PTC (4294CrT [Arg1432Ter]). In this last instance, the mRNA was stable but led to synthesis of a truncated
protein that was not incorporated into mature type III procollagen molecules. In all probands, the presenting feature
was vascular aneurysm or rupture. Thus, in contrast to mutations in genes that encode the dominant protein of a
tissue (e.g., COL1A1 and COL2A1), in which “null” mutations result in phenotypes milder than those caused by
mutations that alter protein sequence, the phenotypes produced by these mutations in COL3A1 overlap with those
of the vascular form of EDS. This suggests that the major effect of many of these dominant mutations in the
“minor” collagen genes may be expressed through protein deficiency rather than through incorporation of struc-
turally altered molecules into fibrils.
Introduction
Ehlers-Danlos syndrome (EDS) type IV (EDS type IV
[MIM 130050]), the vascular or ecchymotic type (Beigh-
ton et al. 1998), is a dominantly inherited disorder that
results from mutations in the COL3A1 gene, which en-
codes the constituent chains of type III procollagen (Pope
et al. 1977; Byers and Schwarze, in press). Many affected
individuals have fragile, thin, or translucent skin through
which the venous pattern is readily visible. They gen-
erally bruise easily and often have unexplained ecchy-
moses in well-protected areas. Some have a “character-
istic” facies with tight skin, thin nose, and a “stare”
(Pope et al. 1980, 1988). Large-joint mobility is gen-
erally normal, with hypermobility limited to the small
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joints of the hands. The major complications are arterial,
bowel, and uterine rupture. Because of these dramatic
complications, life expectancy is shortened to a mean of
!50 years (Pepin et al. 2000).
The causative gene, COL3A1 (accession numbers
193023938–193062278 in the Human Genome Project
Working Draft at UCSC), located at 2q31-q32, contains
52 exons (of which exons 4 and 5 are fused to create
a single exon) distributed over 44 kb (Chu and Prockop
1993). New mutations are common, and approximately
one-half of identified individuals with the condition
have no apparent family history of the disorder. More
than 200 mutations in the COL3A1 gene have been
identified (Kuivaniemi et al. 1997; Pepin et al. 2000)
(see the “Mutations in COL3A1” database), all of
which lead to synthesis of an abnormal type III pro-
collagen protein. Approximately two-thirds of the mu-
tations are single-nucleotide substitutions that result in
substitutions for glycine residues in the triple-helical do-
main of the proa1(III) chain. Most of the rest are splice-
site mutations that result in exon skipping, although
some have more-complex outcomes (Kuivaniemi et al.
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Table 1
Restriction Enzymes Employed to Distinguish between Alleles—and Primers Used to Amplify







DdeI 1851G/A (exon 27):
Genomic DNA GCTCCTGGTAAGAATGGAGAACG (exon 26) 58
GGGTCCTGTGTCTCCTTTGTC (exon 28)
cDNA TCCTGGAAAGAATGGTGAAACTG (exon 27) 60
CTTGCCTCCTGGAGCTCCAGGTG (exon 30)
SpeI 2092G/A (exon 31):
Genomic DNA AAGTATACAAATTTCTAGATTG (intron 30) 46
CTCCTTCGGGACCAGGGGGACTAG (exon 31)a
cDNA GTGATGCCGGTGCACCTGGAGCT (exon 30) 60
CTCCTTCGGGACCAGGGGGACTAG (exon 31)a
AluI 2092G/A (exon 31):
Genomic DNA AAGTATACAAATTTCTAGATTG (intron 30) 46
ATAAATGATCAGAAGGAAATCA (intron 31)b
cDNA GTGATGCCGGTGCACCTGGAGCT (exon 30) 58
GCAAGCTTTCCCTGGGACACCAT (exon 33)b
2244C/T (exon 33):
Genomic DNA (HaeIII) CAACACTCCTGGAAAGTAATCG (intron 32) 56
AGTGCAGGACTGTCCCATATG (intron 33)
cDNA (Fnu4HI) AGGAATTCCTGGAGAAAGAGGAG (exon 32) 60
TTCACCTTTGACACCTTGGGGA (exon 38)
a Underscored is the mismatched nucleotide introduced to create a SpeI site.
b Antisense primer end-labeled with g[32P]-ATP (3,000 Ci/mmol; Amersham) by T4 polynucleotide
kinase (New England BioLabs) and added to the last cycle of a PCR that consisted of 26 cycles to
prevent heteroduplex formation and an artificial bias of cut:uncut product ratio.
1990; Schwarze et al. 1997), and a small number are
larger genomic deletions (Kuivaniemi et al. 1997). No
correlations have been discerned between the nature or
location of the mutation and the type or frequency of
major complications (Pepin et al. 2000).
To date, no COL3A1 mutations that result in loss of
transcript stability—and, thus, in half-normal amounts
of type III procollagen—have been reported. One hy-
pothesis to explain the failure to identify this class of
mutations is that the phenotype caused by COL3A1
haploinsufficiency differs, with respect to its severity or
its symptomatic range, from the usual presentation of
EDS type IV and has been excluded from analysis. Het-
erozygous mice with a Col3a1 null allele generated by
targeted gene inactivation were phenotypically normal
(Liu et al. 1997), although late onset of signs would
have been missed if they had occurred after the follow-
up period of 18 mo. The notion that milder or late-
onset vascular involvement may be a candidate phe-
notype for the COL3A1 null-allele genotype was
weakened by the data from two large studies of indi-
viduals with cerebral aneurysms (Kuivaniemi et al.
1993) and abdominal aortic aneurysms (Tromp et al.
1993), inasmuch as the majority of affected individuals
had evidence of expression of both COL3A1 alleles.
We have now identified mutations in four individuals
that resulted in effective COL3A1 haploinsufficiency.
Each of the individuals had a clinical course compatible
with EDS type IV, with significant morbidity due to vas-
cular complications. There were two molecular mecha-
nisms. In three of the individuals, frameshift muta-
tions resulted in premature termination codons (PTCs)
and nonsense-mediated decay (NMD) of mRNA; in the
fourth individual, a nonsense mutation, in the terminal
exon, which resulted in a PTC, was associated with both
stability of the mRNA and a shortened protein that failed
to participate in trimer formation and that thus reduced
the amount of the mature molecule produced.
Subjects, Material, and Methods
Clinical Summary
Thirty-nine individuals whose cells appeared to make
only type III procollagen molecules of normal mobility
were selected, to determine whether mRNA from both
COL3A1 alleles was present. On the basis of clinical
evaluation, EDS type IV was the most likely diagnosis
in 26 individuals and (because of familial aneurysms or
spontaneous pneumothorax) was a reasonable differ-
ential diagnosis in 6 individuals. Five additional indi-
viduals who had signs consistent with classic EDS (i.e.,
EDS types I/II) were studied to rule out EDS type IV.
Two additional individuals had been diagnosed with
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Table 2







G allele CTGAATTCCAGGGAACAACTTGATG (exon 1) BsrBI
CTCCTTCGGGACCAGGGGGACCCG (exon 31)b
GGCCCCAGGACTTAGAGGTGCA (exon 31)b BsgI
TGATCCATGTATGCAATGCTAT (exon 51)
A allele CTGAATTCCAGGGAACAACTTGATG (exon 1) SpeI
CTCCTTCGGGACCAGGGGGACTAG (exon 31)b
GGGCCCCAGGACTTAGAGTTCGA (exon 31)b BstBI
AGGTAGTCTCACAGCCTTGCGTGT (exon 52)
a Allowed selective digestion of stable allele.
b Underscored is (are) the mismatched nucleotide(s) introduced to create, for the restriction
enzyme shown, a recognition sequence on the stable allele.
EDS type VIII. In the first group, cells from 3 (individuals
P1–P3) of 26 individuals expressed stable COL3A1
mRNA from only one allele and were selected for further
studies; also in the first group, in cells from 5 additional
individuals, which had stable COL3A1 mRNA expres-
sion from both alleles, the region of mRNA encoding
the C-propeptide was sequenced directly, and one ab-
normality (in individual P4) was identified.
Individual 1 (P1) was a 31-year-old female with char-
acteristic physical findings: a “pinched” nose, thin lips,
lobeless ears, scant subcutaneous tissue with easily visi-
ble veins, multiple ecchymoses, numerous wide scars
from surgical procedures, and hypermobility of the finger
joints. Easy bruisability since childhood was reported. At
age 21 years, she had undergone colectomy because of
“polyposis coli,” and the bowel tissue was noted to be
paper thin. Several laparotomies for the repair of entero-
cutaneous fistulae were complicated by bowel anasto-
moses and wound dehiscence. At age 29 years, rupture
of a common-hepatic-artery aneurysm resulted in a large
retroperitoneal hematoma that required surgical inter-
vention, and the blood vessels were described as very frag-
ile. Postoperative angiography showed a renal aneurysm
and a superior-mesenteric-artery dissection. At age 30
years, a sciatic-nerve palsy developed because of a spon-
taneous gluteal hematoma. At age 31 years, she experi-
enced a subarachnoid hemorrhage. Cerebral angiography
revealed multiple aneurysms and marked tortuosity of all
cervical arteries. During surgery, the ophthalmic artery,
after very minor manipulation, tore off the carotid artery,
which resulted in a massive cerebral infarct from which
the patient died. The patient’s mother and sister had a
similar facial appearance, very thin skin, easy bruisability,
and several vascular events, including vertebral- and in-
ternal-carotid-artery dissections resulting in brain-stem
and hemispheric infarcts.
Individual 2 (P2) is a 46-year-old female who had a
history of easy bruising with minor or no trauma and
some hypermobility of the small joints of her hands. Her
skin was not translucent but showed markedly decreased
mechanical strength when a punch biopsy was per-
formed. At age 44 years, she presented to the emergency
room with an atraumatic hemoperitoneum and hem-
orrhagic shock. Exploratory laparotomy revealed mul-
tiple bleeding vessels; bleeding from the spleen, from the
pancreatic tail bed, and from lacerations of the liver;
and a torn mesocolon. During surgery, tissue friability
was not noted to be abnormal, but the postoperative
course was complicated by signs of continued bleeding
that required re-exploration. Postoperative angiography
showed numerous aneurysms of multiple large- and me-
dium-size abdominal arteries and a distal abdominal
aortic aneurysm with diffuse dilatation of the common
iliac arteries and of the external and internal iliac ar-
teries. Smaller wounds usually healed well, with wide
scars, whereas the surgical wounds caused chronic prob-
lems, with herniations of viscera, which have required
repeated hospitalization. This individual’s family history
is remarkable only for easy bruisability, by report, in her
mother and for facial features in one of her daughters
that are reminiscent of EDS type IV.
Individual 3 (P3) is a 48-year-old male with soft, vel-
vety, and translucent skin and some atrophic scars on
his lower extremities. He had no major illness until age
47 years, when he had sudden onset of headache fol-
lowed by acute left-flank pain. Abdominal computed
tomography (CT) revealed multiple infarcts in the left
kidney, and subsequent angiography showed dissec-
tion of the left renal artery, with clot formation in the
false lumen. Ultrasonography of the carotid arteries re-
vealed no abnormalities. A few days later, this individual
had another acute episode of abdominal pain. Angiog-
raphy revealed multiple dissections involving the splenic
and hepatic branches of the celiac artery and both renal
arteries, as well as occlusion of the gastroduodenal ar-
tery. He became critically ill, with signs of cardiovascular
instability, adrenal insufficiency, and acute respiratory
failure. Because of developing symptoms of abdominal-
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Figure 1 SDS-PAGE of radiolabeled procollagens from medium and fibroblasts cell layer, analyzed under reducing conditions, from a
control cell line (lanes C) and cell strains from four individuals with EDS type IV (P1–P4). In cells from P1 the diminution in the amount of
proa1(III) is evident, but it is not clear in the other three individuals. FN p fibronectin.
Figure 2 Demonstration of loss of expression of one COL3A1
allele in three of four individuals with EDS type IV. A, Heterozygosity
for the exon 31 (2092G/A) polymorphism assayed as a SpeI site in
genomic DNA (left) from P1 and P2. The cDNA from P1 contained
only the SpeI() allele. In the cDNA from P2, only the SpeI () allele
was stable. B, Amplification products for the AG insertion/deletion in
the 3′UTR, separated on MDE gel. In genomic DNA from P3 (left lane)
both alleles were detectable in equal amounts, whereas in cDNA (right
lane) only the AG-insertion allele was present, which resulted in the
disappearance of the heteroduplex (H). C, Heterozygosity for the exon
33 (2244C/T) polymorphism assayed as a HaeIII site in genomic DNA
(left) from P4. In cDNA, after digestion with Fnu4HI, both alleles were
present in P4, comparable to the heterozygous control.
compartment syndrome, he underwent exploratory lap-
arotomy with temporary closure and mesh placement.
He had good wound healing after the procedure, but
skin grafting was required for complete closure of the
abdominal wall. Bilateral abdominal tissue expanders
were placed, with a gradual increase in the injected vol-
ume. A few months after this procedure, a rupture of a
subcutaneous vessel occurred. Except for a large super-
ficial hematoma, an abdominal CT did not disclose other
abnormalities. Surgery for abdominal-wall closure is
planned. There are no other family members with clin-
ical signs consistent with EDS type IV.
Individual 4 (P4) is a 46-year-old black female with
a lifelong history of easy bruising. At age 45 years, she
was evaluated for anemia and heavy menses. Pelvic ul-
trasonography and abdominal CT revealed an aneurysm
of the left common iliac artery. Three months later, she
had sudden onset of severe abdominal pain, at which
time CT and angiography revealed a new infrarenal ab-
dominal aortic aneurysm and a dissection extending
from the infrarenal aorta to the left common iliac artery.
She underwent surgery, with ligation of the infrarenal
abdominal aorta combined with an axillobifemoral by-
pass and fenestration of the iliac dissection. The post-
operative course was complicated by dehiscence of the
axillary anastomosis, which required surgical revision,
from which she recovered without further complica-
tions. The proband’s parents died in their 60s, the father
from cancer and the mother from unknown cause during
her sleep, so that the diagnosis of EDS type IV in the
mother cannot be excluded. Of the proband’s three sis-
ters (who were ages 54, 52, and 48 years), the oldest
was evaluated for EDS type IV, because of easy bruising,
soft and thin skin, hypermobile joints, inguinal hernias,
aneurysmal dilatation of the superior mesenteric artery,
and repeated colorectal surgeries due to frequent epi-
sodes of abdominal pain, bowel obstruction, and fistulae
in the absence of inflammatory bowel disease. In the two
younger sisters, no vascular complications or sponta-
neous bowel perforation have been reported. The pro-
band’s only child (a 15-year-old male) is healthy.
Cell Culture and Analysis of Collagenous Proteins
Dermal fibroblasts were obtained from explants of
skin-biopsy specimens from the four individuals, after
appropriate consent had been obtained. Growth and
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Figure 3 Amplification of COL3A1 exon 27 in genomic DNA from P1 and from a control individual. A, Apparent heteroduplex (H) in
P1, owing to deletion of 2 bp in one COL3A1 allele. B, Nucleotide sequence in the normal (left four lanes) and mutant (right four lanes) alleles
from P1. The two deleted nucleotides (AA) are in boldface in the letter code for the normal sequence. The consequence of the 2-bp deletion
in P1 is a PTC (boxed triplet) immediately downstream of the deletion site.
Figure 4 COL3A1 exon 4/5 genomic sequence around the 1-bp
deletion (underlined) in P2.
maintenance of those fibroblasts and of control cell
strains, radiolabeling of collagenous proteins, and anal-
ysis of proa chains and a chains by SDS-PAGE were
performed as described elsewhere (Bonadio et al. 1985).
Preparation of cDNA and Genomic DNA, and
Analysis of Expressed Polymorphisms in COL3A1
Total cellular RNA and genomic DNA were extracted
from cultured dermal fibroblasts from P1–P4 and of con-
trols, by RNeasy Mini Kit (Qiagen) and QIAamp DNA
Mini Kit (Qiagen), respectively. In addition, nuclear and
cytoplasmic RNA were prepared from cultured fibro-
blasts from P1, P3, and a control cell strain, which were
incubated in the absence or presence of cycloheximide
(CHX [100mg/ml]) for 6 h before the cell harvest, by
guanidinium thiocyanate-phenol-chloroform extraction
(Chomczynski and Sacchi 1987), as described elsewhere
(Schwarze et al. 1999). Complementary DNA was syn-
thesized by priming with random hexamers in the pres-
ence of Superscript II reverse transcriptase (Gibco BRL)
in total RNA or in nuclear/cytoplasmic RNA after treat-
ment with DNase I (Boehringer-Mannheim) for 20 min
at 37C with the incubation buffer recommended by the
manufacturer. To check for residual genomic DNA in
the RNA preparation, a control PCR was performed
without prior reverse transcription.
Three single-nucleotide polymorphisms, in exons 27,
31, and 33, and an “AG” insertion/deletion polymor-
phism in the 3′UTR of COL3A1, with a combined het-
erozygosity of ∼.80, were analyzed in genomic DNA and
cDNA (cDNA reference sequence is GenBank acces-
sion number NM_000090). Fragments were amplified,
cleaved with the appropriate restriction enzyme, and
separated by PAGE. The polymorphic variants used were
G/A at nucleotide 1851 (with reference to the A of the
initiating methionine, which is considered to be nucle-
otide 1 in the cDNA sequence) in exon 27 (Tromp et
al. 1993), G/A at nucleotide 2092 in exon 31 (Zafarullah
et al. 1990), and C/T at nucleotide 2244 in exon 33
(Tromp et al. 1991). 1851G/A was assayed as a DdeI
site; 2092G/A as a SpeI site, by use of a mismatch primer
(table 1), and also as an AluI site for P1; and 2244C/T
as a HaeIII site in genomic DNA and as a Fnu4HI site
in cDNA. The amplification primers are listed in table
1. Unless otherwise specified, all amplifications consisted
of 35 PCR cycles.
Heterozygosity screening for an AG insertion/deletion
polymorphism in the 3′UTR of COL3A1 (U. Schwarze,
unpublished data) was performed by amplification of a
568–570-bp fragment, by use of primers 5′-TCTTTGA-
ATCCTAGCCCATCTG-3′ and 5′-TGTGACAAAAGC-
AGCCCCATAA-3′ (10 s at 95C, 20 s at 55C, and 35
s at 72C, for 35 cycles) and separation of the products
both on 6% acrylamide and on MDE (BMA) gels. The
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Figure 5 A, Amplification of COL3A1exons 6–13 in cDNA of
a control individual and in P3. Complementary DNA was derived from
either total cellular RNA, nuclear RNA, or nuclear RNA, after treat-
ment with CHX (100 mg/ml). When nuclear RNA was used, in P3 a
heteroduplex (H) became visible that was barely detectable in total
RNA and that was not enhanced by treatment with CHX. B, Exon 7
genomic sequence around the 1-bp deletion (underlined) in P3, ob-
tained by an antisense sequencing primer located in intron 7.
nucleotide sequence of the 3′UTR was derived from
GenBank (accession number NM_000090). 5302A was
either deleted or replaced by AG.
Identification of Mutations That Led to Unstable
mRNA in P1 and P2
Depending on which allele was determined to be stable
on the basis of the analysis of 2092G/A in exon 31, the
primers listed in table 2 were used to amplify theCOL3A1
coding sequence in two large fragments, through 15 cy-
cles. A 10-ml aliquot was digested with the appropriate
restriction enzyme (table 2), under conditions recom-
mended by the manufacturer (New England BioLabs),
and a 2-ml aliquot was reamplified through 35 cycles with
the same primer pairs that had been used for the initial
amplification. The second amplification preferentiallyam-
plified the allele that had not been cut (i.e., the unstable
allele), and the products were separated on 6% poly-
acrylamide gels and were excised from the gel. The gel
slices were submerged in dH2O overnight at room tem-
perature, and the supernatant was used to amplify, in 15
overlapping fragments, the COL3A1 coding sequence.
The sequences of the primers (see the Appendix, published
in the online version) were derived from the previously
published cDNA sequence for COL3A1 (Ala-Kokko et
al. 1989; Benson-Chanda et al. 1989). The PCR fragments
were separated on 6% polyacrylamide gels. If a heterodu-
plex was generated, this fragment was sequenced selec-
tively. If all fragments were indistinguishable from the
control, then all fragments were sequenced with the am-
plification sense primer. Sequence was determined either
by the dideoxy-chain–termination method (Sanger et al.
1977) using T7 polymerase (Sequenase version 2.0; US
Biochemicals) after the fragment of interest was directly
cloned into the PCR II vector, according to instructions
provided in the TA cloning kit (Invitrogen), or by an ABI
PRISM BigDye Terminator cycle sequencing reaction and
ABI PRISM 310 Genetic Analyzer (Perkin-Elmer Applied
Biosystems). Identified mutations were confirmed in ge-
nomic DNA by amplification of the region of interest,
followed by direct sequencing.
Identification of the Mutation That Led to Unstable
mRNA in P3
Complementary DNA synthesized from nuclear RNA
from P3 and from a control was used to amplify, in 15
overlapping fragments, theCOL3A1 coding sequence (see
above), and the products were separated on 6% poly-
acrylamide gels. Heteroduplex bands in P3 were excised
from the gel and were submerged in dH2O overnight at
room temperature, and the supernatant was used for
reamplification by the same primer pair. The mutation
was confirmed in genomic DNA by direct sequencing.
Mutation Identification in P4
The region of COL3A1 cDNA that encodes the car-
boxyl-terminus was amplified by primers in exon 45
(5′-TCCTGCTGGTTCCCGAGGTG-3′) and exon 52
(5′-GTTGACAAGATTAGAACAAGAGGAACA-3 ′)
and were directly sequenced with the amplification
primers. The mutation was confirmed in genomic DNA
by the restriction endonuclease SspI.
Western Blot Analysis of Type III Procollagen
Proa chains from the medium and from the cell layer
of cultured fibroblasts from P1 and from a control cell
strain were separated by SDS-PAGE (7%) under reducing
conditions, were transferred to nitrocellulose membrane,
and were immunodetected by LF-72 antiserum (a poly-
clonal antibody that binds the amino-terminal telopeptide
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Figure 6 Comparison of RNA stability in pre-mRNA and in nuclear and cytoplasmic RNA from P1. The two COL3A1 alleles were
distinguishable after restriction digestion with AluI, owing to heterozygosity for 2092G/A. The AluI():AluI () allele ratio in pre-mRNA from
P1 was similar to that seen in the heterozygous control. In nuclear (lanes Nu) RNA the AluI() allele was markedly reduced, and in cytoplasmic
(lanes Cp) RNA it was barely detectable. The treatment of cells with CHX prior to RNA isolation resulted in increased appearance of the
AluI() allele in both cellular compartments.
Figure 7 Heterozygosity for a nonsense mutation identified in
P4, in exon 52 of COL3A1. A, Sequence around the site of the mu-
tation obtained by an antisense sequencing primer. The substitution
of T for C resulted in the conversion of a codon for arginine (CGA)
to a PTC (TGA). B, Restriction digestion, with SspI, of genomic-am-
plification products from a control individual and from P4. The mu-
tation shown in panel A created a recognition sequence for SspI.
of proa1(III), which was kindly provided by Larry Fisher
of the National Institute of Dental Research) (Fisher et
al. 1995) and ECL reagents (Amersham).
Pulse-Chase Analysis of Procollagen Assembly
Fibroblasts from P4 and from a control cell strain were
preincubated in serum-free medium and ascorbic acid
for 4 h and then were pulse-labeled with 200 mCi of
tritiated proline (85–130 Ci/mmol; Amersham) for 80
min. For chase, cells were rinsed with serum-free me-
dium supplemented with 10 mM proline and were in-
cubated in the same medium for 0, 20, 40, 60, or 80
min. Proteins from the medium and proteins from the
cell layer were harvested separately by ethanol precipi-
tation and were analyzed by SDS-PAGE under nonreduc-
ing conditions.
Results
Analysis of Type III Collagen Production by Patients’
Cultured Fibroblasts
Radiolabeled procollagens from the medium and from
the fibroblast cell layer were analyzed by SDS-PAGE,
first after addition of a reducing agent (fig. 1) and then
under nonreducing conditions after partial digestion,
with pepsin, to remove the precursor-specific peptides at
both ends of the triple-helical domain (not shown). In
all cell strains (i.e., P1–P4), there was no overmodifi-
cation or intracellular retention of proa1(III) chains and,
thus, no evidence of a structural defect (fig. 1). Only in
P1 did the amount of structurally normal type III pro-
collagen secreted into the medium appear to be sub-
stantially diminished relative to the amount of type I
procollagen and compared to that in the control cell
strain (fig. 1).
A Single Stable COL3A1 Allele in Cells from Three
Patients with EDS type IV
Although the evidence of reduced synthesis of type III
procollagen was limited to a single cell strain, the clinical
profile of all probands was sufficient to warrant further
investigation to determine whether bothCOL3A1 alleles
were effectively expressed. Samples of genomic DNA
were analyzed for heterozygosity of COL3A1 markers.
P1 and P2 were heterozygous for 2092G/A in exon 31
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Figure 8 Pulse-chase analysis of procollagen assembly. Cells from a control and from P4 were pulse-labeled, and the cell-layer proteins
were harvested either immediately or after differing periods of chase and were separated by SDS-PAGE under nonreducing conditions. In control
cells, proa1(III) chain monomers were detectable only at times 0 min and 20 min. In P4, proa1(III) chain monomers with increasingly delayed
electrophoretic mobility were detectable throughout the entire chase period, whereas the proa1(I) chains that migrated directly below the
proa1(III) chains had completely disappeared at 60 min, in both the control and P4, owing to incorporation into dimers and trimers of type I
procollagen, which are denoted by “D(I)” and “T(I),” respectively]. FN p fibronectin.
(fig. 2A). When cDNA amplified from exon 30 to exon
31 was digested with SpeI, in the sample from P1, only
the G allele, SpeI(), was detectable. In the cDNA sam-
ple from P2, the abundant species was the A allele,
SpeI(), although there was a very small amount of the
G allele present (fig. 2A). P3 was homozygous, in ge-
nomic DNA, for the markers in exons 27, 31, and 33
but was heterozygous for the AG insertion/deletion in
the 3′UTR. When cDNA was amplified and analyzed by
PAGE, the heteroduplex that indicated the presence of
both alleles in genomic DNA was greatly diminished (not
shown). Separation of genomic and cDNA amplification
products on MDE gel showed that only transcripts de-
rived from the AG-insertion allele were stable (fig. 2B).
P4 was heterozygous, in genomic DNA, for 2244C/T in
exon 33, and both alleles were detectable in cDNA, in
amounts comparable to those in the heterozygous con-
trol individual (fig. 2C).
Identification of Mutations That Led to Unstable
mRNA
After enrichment for the unstable allele (see the Sub-
jects, Material, and Methods section), analysis of
cDNA from P1 revealed a heteroduplex in the ampli-
fication product that extended from exon 22 to exon
28 (not shown). Excision of the heteroduplex bands
and reamplification with the same primer set, followed
by sequencing, identified a 2-bp deletion in exon 27
(1831–1832delAA) and, in the same exon, a PTC (i.e.,
TGA) 3 nucleotides downstream of the deletion site. The
mutation was confirmed by amplification of exon 27 in
genomic DNA (fig. 3A) and sequence determination af-
ter separation of the normal and mutant allele by the
TA cloning procedure (fig. 3B).
Because the same approach to analysis of cDNA from
P2 failed to demonstrate a heteroduplex, all 51 exons were
sequenced after amplification, in 15 overlapping frag-
ments, of the COL3A1 cDNA. The amplification product
that spanned exons 2–8 showed superimposition of two
sequences, because of a 1-bp deletion located within six
consecutive C’s in fusion exon 4/5 (413delC), affecting
the 12th of 13 Gly-Xaa-Yaa repeats that encode the minor
triple helix of the N-propeptide. Consequent to the C
deletion, a PTC (i.e., TAG) was encountered 77 nucleo-
tides downstream in the N-telopeptide–encoding portion
of exon 6. The mutation was confirmed by amplification
of exon 4/5 in genomic DNA and direct sequencing (fig.
4; a four-color version of fig. 4 is available in the on-line
edition of this article).
In P3, amplification, in 15 overlapping fragments, of
COL3A1 cDNA, derived from nuclear RNA, revealed
a heteroduplex in the fragment that extended from exon
6 to exon 13 (fig. 5A; a four-color version of fig. 5 is
available in the on-line edition of this article). Exposure
of cultured fibroblasts to cycloheximide (100 mg/ml) for
6 h before isolation of nuclear RNA did not enhance
the appearance of the heteroduplex (fig. 5A). Excision
of the heteroduplex bands, reamplification with the same
primer set, and direct sequencing identified a 1-bp de-
letion in exon 7 (555delT) and a PTC (i.e., TAG) 80
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nucleotides downstream in exon 9. The mutation was
confirmed by amplification of exon 7 in genomic DNA
and direct sequencing (fig. 5B).
Comparison of RNA Stability in pre-mRNA and in
Nuclear and Cytoplasmic RNA in P1
Exon 31 was amplified in genomic DNA and cDNA
derived from pre-mRNA (by use of the nuclear-RNA
preparation), with primers in introns 30 and 31 (table
1), and in cDNA derived from nuclear and cytoplasmic
RNA, with primers in exons 30 and 33 (table 1). The
respective antisense primer was end-labeled with g[32P]-
ATP (3,000 Ci/mmol; Amersham) by T4 polynucleotide
kinase (New England BioLabs) and was added to the
last cycle of a PCR, which consisted of 26 cycles, to
prevent heteroduplex formation and an artificial bias of
the cut:uncut product ratio. All amplification products
were digested with AluI. The AluI():AluI () allele
ratio in pre-mRNA from P1 was identical to that seen
both in genomic DNA from P1 and in pre-mRNA and
genomic DNA from the heterozygous control (fig. 6). In
nuclear RNA, the AluI() allele (2092A) appeared to
be markedly reduced, and it was barely detectable in
cytoplasmic RNA (fig. 6). The addition of cycloheximide
(100 mg/ml) to cultured fibroblasts for 6 h prior to RNA
isolation resulted in partial stabilization of the unstable
AluI() allele in both the nuclear and cytoplasmic com-
partments (fig. 6).
Western Blot Analysis of Secreted Type III Procollagen
in P1
The location of the PTC in transcripts from the mutant
allele in P1 predicted truncated proa1(III) chains of ∼67
kD, yet the transcript instability demonstrated earlier
made it unlikely that those shortened chains were syn-
thesized and secreted into the medium. Immunodetection
of type III procollagen by an antibody against the N-
telopeptide yielded a signal only for full-length proa1(III)
chains, in both medium and cell layer and, in addition,
for partially converted chains, pNa1(III), from which the
C propeptide had been removed, in the medium (not
shown).
Identification of a Nonsense Mutation in P4 That Did
Not Affect mRNA Stability
In P4, although mRNA from both COL3A1 alleles
was found to be stable, the most carboxyl-terminal ex-
ons were sequenced in cDNA, to exclude the possibility
of a PTC that did not affect mRNA stability but that
resulted in truncated proa1(III) chains that either im-
paired or were excluded from proper chain trimeriza-
tion. Direct sequencing of the cDNA fragment that com-
prised exons 45–52 identified, in exon 52, a nonsense
mutation (4294CrT [R1432X]) that predicted trunca-
tion by 35 amino acid residues of proa1(III) chains de-
rived from the mutant allele (fig. 7A; a four-color version
of fig. 7 is available in the on-line edition of this article).
The truncation led to elimination of the most-carboxyl-
terminal of eight cysteine residues in the C propeptide
(C1464), a residue that forms an intrachain disulfide
bond with the cysteine at position 1302, a process that
precedes chain association into trimers. The mutation
was confirmed in genomic DNA by the restriction en-
donuclease SspI, a recognition site for which was created
by the nucleotide substitution (fig. 7B). Restriction di-
gestion demonstrated the presence of the mutation also
in the proband’s three sisters but its absence from the
proband’s son.
Pulse-Chase Analysis of Procollagen Assembly in P4
Because intrachain disulfide-bond formation in the C
propeptide precedes chain trimerization during pro-
collagen assembly, the effect that the absence of the
most-carboxyl-terminal cysteine residue in shortened
proa1(III) chains in P4 had on incorporation into trimers
was examined by labeling of proteins with [3H]proline
for 80 min and chase, for 80 min, with excess unla-
beled proline (fig. 8). In the cell layer of control fibro-
blasts, proa1(III)-chain monomers disappeared after
20–40 min (fig. 8). In contrast, in P4, defective proa1(III)
chains persisted as monomers, with increasingly delayed
electrophoretic mobility, for 180 min and were not rap-
idly degraded. To address the possibility that small
amounts of defective proa1(III) chains were participat-
ing in trimer formation and were being secreted, proteins
harvested from the medium layer during pulse-chase
were separated by SDS-PAGE under reducing condi-
tions, were transferred to nitrocellulose membrane, and
were immunodetected by LF-72 antiserum. Both in the
control and in P4, proa1(III) chains of normal length
were detected, and there was no evidence of shortened
chains in P4 (not shown).
Discussion
Because mice heterozygous for a nonexpressed Col3a1
allele were reported to have no vascular phenotype (Liu
et al. 1997), it was unexpected that people with either
similar mutations or mutations that resulted in secretion
of only half the normal amount of type III procollagen
would have arterial fragility. It is striking that, in the
present study, the individuals in whom we identified
COL3A1 “null” mutations had a clinical course similar
to that seen in individuals with EDS type IV (Pepin et
al. 2000), all of whom had mutations that affected the
structure of type III procollagen. All individuals in the
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present study had significant morbidity due to vascular
rupture, and in at least one family those complications
occurred during the 3d decade of life. There were no
instances of bowel rupture, although the total number
of identified individuals was small and bowel rupture
accounts for only ∼20% of complication in individuals
with mutations in COL3A1 that alter the structure of
the protein product (Pepin et al. 2000). The findings in
our study suggest that a 50% reduction of the amount
of structurally normal type III procollagen is as delete-
rious to the vascular system as are other types of mu-
tations. Because the number of individuals identified is
still small, we are uncertain whether individuals hetero-
zygous for COL3A1 null alleles are more likely to have
a longer time to symptomatic arterial events. The length
of the follow-up period in mice heterozygous for Col3a1
null mutations was ∼18 mo, so late onset of signs of
arterial involvement might have been missed. Alterna-
tively, mouse models might not replicate human disease
phenotypes in all aspects.
Ultrastructural analyses of tissues derived from ho-
mozygous Col3a1/ mutant mice, which have a phe-
notype that resembles human EDS type IV, have shown
that the tissues most affected were those which have the
greatest amount of type III collagen and are most se-
verely affected in EDS type IV (Liu et al. 1997). No
studies of the heterozygous mice have been described.
In the Col3a1/ mice, collagen fibrils were either absent
from or severely reduced in number in the tunica media
of the aorta. The diameter of collagen fibrils in the ad-
ventitia of the aorta was highly variable, and the num-
ber of fibrils was reduced to approximately one-third
that in the normal aorta. The collagen fibrils in the skin
were disorganized and highly variable in diameter; and
collagen fibrils were either absent from or markedly
reduced in number in the submucosa and serosa of the
intestine. The collagen fibrils in all the tissues studied
consist primarily of type I collagen, so it is likely that
type III collagen plays an important role in the early
organization of the collagenous network that provides
tensile strength to these tissues.
Mutation analysis in individuals in whom the diag-
nosis of EDS type IV was made on clinical grounds has
been very productive when cultured fibroblasts synthe-
sized a cohort of abnormal type III procollagen mole-
cules. In all instances identified thus far, the underlying
mutations occur in one COL3A1 allele and result in
either substitutions for single-glycine residues in the tri-
ple-helical domain of proa1(III) chains, small in-frame
deletions, or splice-site mutations (Kuivaniemi et al.
1997; Pepin et al. 2000; Byers and Schwarze, in press)
(see the “Mutations in COL3A1” database). In each
instance, the effect of an abnormal allele product is am-
plified, since type III procollagen is a homotrimer. As a
consequence, an abnormal product from one allele is
expected to result in seven of eight molecules being ab-
normal. In contrast, the mutations described here ap-
pear simply to reduce the amount of type III collagen
in a tissue, by virtue of either loss of the mRNA products
of one allele or inability of the protein product to as-
semble into trimers. COL3A1 mutations that result in
either loss of stable transcript or in functional loss of
the protein products of one COL3A1 allele of type III
procollagen appear to be either rare or difficult to iden-
tify, since we are unaware of additional examples of
these types of mutations among the 1200 mutations that
have been compiled in the COL3A1 mutation database.
Heterozygosity for mutations that lead to loss of the
products of one allele have been identified in several
other fibrillar collagen genes, including COL1A1 (Will-
ing et al. 1990, 1994, Willing et al. 1996; Stover et al.
1993; Redford-Badwal et al. 1996; Korkko et al. 1998;
Ward et al. 2001), COL2A1 (Kuivaniemi et al. 1997;
Freddi et al. 2000), and COL5A1 (Schwarze et al. 2000;
Wenstrup et al. 2000). This class of mutations in the
COL1A1 and COL2A1 genes leads to reduced pro-
duction of their allele products and to the mildest of
the phenotypes that result from mutations in those
genes: osteogenesis imperfecta type I, in the case of the
COL1A1 gene, and Stickler syndrome, in the case of
the COL2A1 gene. In both instances, the genes encode
the major protein products in the tissues in which they
are expressed (type I procollagen/collagen and type II
procollagen/collagen), the mutations reduce the amount
of each mature protein to half-normal levels, and the
proteins made are normal. In contrast, mutations in
COL5A1 that alter either the amount produced or chain
structure of type V collagen molecules, a minor product
in most tissues, appear to have similar phenotypes—the
EDS type I/II clinical picture. This effect is similar to
that seen with the different types of mutation in the
COL3A1 gene and thus may be characteristic of genes
that do not encode the major structural product of the
tissue.
Given the model of COL1A1 and COL2A1 genes in
which haploinsufficiency mutations produce a milder
variant of the more severe phenotype, it had been ex-
pected that such would be the case for mutations in the
COL3A1 gene. Candidate phenotypes included isolat-
ed aneurysmal disease, but studies of individuals with
either cerebral (Kuivaniemi et al. 1993) or abdominal
aortic (Tromp et al. 1993) aneurysms failed to identify
COL3A1 mutations, and the majority of affected indi-
viduals had evidence of expression of both alleles. Be-
cause the study was done by direct sequence analysis of
cDNAs, nonexpressed alleles or unstable mRNA prod-
ucts would not have been detected in the minority of
individuals who were homozygous (or hemizygous) at
known polymorphic sites.
It has been difficult to correlate either the nature of
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the mutation, the type of substitution for glycine in the
triple helix, the location of exon skipping, or the presence
of insertions or deletions with variations in the phenotype
that result from mutations in the COL3A1 gene. Pope
et al. (1996) have suggested that individuals with mu-
tations that alter sequences near the carboxyl-terminal
end of the triple helix are more likely to have acrogeria.
We noted a paucity of bowel rupture among individuals
who had substitutions for glycine in the C-terminal quar-
ter of the triple helix; but their ages were younger, and
we could not determine whether the difference was sig-
nificant (Pepin et al. 2000). The factors that might be
considered to be variables in a “severity” scale include
age at first major event (e.g., arterial rupture or bowel
rupture) and the types of events seen in a family (e.g.,
arterial alone, bowel rupture alone, or both). However,
when the ascertainment criteria include one or more of
these features, it is not surprising that “genotype-phe-
notype” correlations are difficult to identify.
Both the role of type III collagen in tissues and the
mechanisms by which mutations in the COL3A1 gene
produce disease are still largely unknown. Type III col-
lagen is expressed in multiple tissues and usually colo-
calizes with type I collagen in the same fibril (Kadler et
al. 1996). It is especially prevalent in tissues that have
multidirectional extensibility, such as the intestine, large
vessels, and the uterine wall, in which type III collagen
may constitute 35%–45% of the total collagen (Seyer
and Kang 1996). In general, the type III:type I collagen
ratio is inversely proportional to the diameter of the
collagen fibrils, so that highly compliant tissues have
both a higher percentage of type III collagen and thinner
fibrils (Lapiere et al. 1977; Romanic et al. 1991). With
reduced synthesis of type III collagen, an increase in the
proportion of type I collagen is expected to result in
altered physical properties of tissues—including reduced
tissue distensibility, which may lead to vascular and hol-
low-organ rupture.
In the cells that we have described here, there are two
mechanisms by which the production of type III pro-
collagen is reduced. In P1–P3 frameshifts result in PTCs
in exons 27, 6, and 9, whereas in P4 a nucleotide sub-
stitution results in a new termination codon in exon 52,
the last exon of the gene. In the first three cell strains,
the mRNA from the mutant allele is unstable, although,
as demonstrated by the equal amounts of precursor
mRNA in the nucleus of cells from P1, both alleles ap-
pear to be transcribed with the same efficiency. The
mRNA from the mutant allele was stabilized by the
translation inhibitor cycloheximide in cells from P1, al-
though the nuclear precursor RNA in cells from P3 was
less responsive to treatment with the drug. These find-
ings are compatible with degradation of the abnormal
mRNA by the mechanisms of NMD (Maquat and Car-
michael 2001). This cellular strategy identifies PTCs
that are separated from the constitutive termination co-
don by one or more introns, possibly by “marking”
domains just upstream from previous exon-intron
boundaries with proteins that associate with mRNA (Le
Hir et al. 2000; Lykke-Andersen et al. 2000). Transla-
tion then leads to displacement of these “marks,” but,
if translation is terminated prior to the constitutive ter-
mination site, these proteins remain bound, recruit exo-
nucleases to the mRNA, and lead to its degradation
(Lykke-Andersen et al. 2000; Lykke-Andersen 2001).
In the cells from P4, a CrT transition converts a
codon for arginine to a PTC in exon 52, the ultimate
exon of the COL3A1 gene. As predicted by the model,
the mRNA from cells from P4 is stable, transported to
the cytoplasm, and appears to encode a polypeptide
chain that is truncated by 35 amino acids. This protein
is translated but, although reasonably stable, is not in-
corporated into mature type III procollagen molecules,
because it cannot fold into a productive conformation.
The terminal 35 residues include a cysteine that is vital
to the formation of one of the intrachain disulfide bonds
that stabilizes a chain prior to trimer formation. In this
instance, diminished production of type III procollagen
reflects the failure of chain association rather than
mRNA instability.
It has proved difficult to detect reduced production
of type III procollagen by analysis of the proteins pro-
duced by cultured cells. As a result, analysis of the prod-
ucts of the two COL3A1 alleles has been a particularly
valuable adjunct in the search for this type of mutation,
but even that has failed to identify the mutation that
did not result in mRNA instability. Direct genomic anal-
ysis is thus likely to be a more efficient mechanism for
identification of these cells strains, now that the clinical
phenotype has been recognized.
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